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Abstract
Background: With the aim of discovering new natural active extracts against malaria parasites, Icacina senegalensis
was selected after an ethnopharmacological survey conducted on plants used in traditional malaria treatment in
Senegal.
Methods: Different concentrations of the plant extract and fractions were tested on synchronized Plasmodium
falciparum cultures at the ring stage using the parasite lactate dehydrogenase assay. Their haemolytic activity and
in vitro cytoxicity were evaluated. The chromatographic profiles of active fractions were also established.
Results: The plant extract and fractions revealed anti-plasmodial activity (IC50 < 5 μg/mL) with no toxicity
(Selectivity indexes >10). The dichloromethane fraction showed stronger anti-plasmodial activity than the total
extract.
Conclusion: Anti-plasmodial activity and toxicity of I. senegalensis are reported for the first time and showed
promising results in malaria field research.
Background
Despite intensive efforts to control malaria, the disease
continues to be one of the greatest health problems
facing Africa [1]. Then the global scope of malaria and
the spread of drug-resistant Plasmodium falciparum
make the need for improved therapy undeniable. There
were an estimated 247 million malaria cases among 3.3
billion people at risk in 2006, causing nearly one million
deaths, mostly children under five years of age. One
hundred six countries were endemic for malaria in
2009, 45 within the WHO African region [1].
This worsening situation can be explained by resis-
tance of P. falciparum to the current anti-malarial drugs
[2], lack of new therapeutic targets, unaffordability and
poor quality of anti-malarial drugs [3,4] and their bad
storage under tropical conditions [4]. Then an urgent
need for the development of new anti-malarial agents
faces the scientific community.
Traditional medical knowledge based on the use of
natural products from plants has often been the basis
for discovering new drugs. It is estimated that 80% of
many developing countries population still use plant-
based traditional medicines [5]. These natural products
and their derivatives represent almost half of the drugs
approved since 1994 [6] and more than 30% of the cur-
rent anti-malarial market [7].
In this context, an ethnopharmacological survey of
medicinal plants was carried out in Senegal and data
were collected on some plants traditionally used for the
treatment of malaria and fevers. Moreover, a literature
review was conducted and allowed the identification of
Icacina senegalensis A. Juss., a plant with known tradi-
tional medical applications but up to now with no
reported anti-plasmodial activity in scientific literature.
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Then this plant was investigated in this work for its
anti-plasmodial activity.
Until recently, schizont maturation inhibition techni-
que [8] and isotopic in vitro assays were the main
methods used to assess in vitro susceptibility of P. fal-
ciparum to anti-plasmodial drugs. Their use was how-
ever limited by the technical constraints of
reproducibility of schizont production and radioactive
risk management. This explains the revived interest in
the development of replacement methods, such as the
detection of malaria antigen. The sensitive quantifica-
tion of major parasite proteins (Histidine Rich Protein
2, Lactate Dehydrogenase, Aldolase) by sandwich
enzyme-linked immunosorbent assay (ELISA) has
recently gained particular interest [9,10]. In this study
Plasmodium lactate dehydrogenase (pLDH) immuno-
detection assay was used [11].
This is the first scientific demonstration of the anti-
plasmodial activity of I. senegalensis leaf extracts in a
standard in vitro assay based on pLDH detection. The
cytotoxicity of extracts was also evaluated.
Methods
Ethnopharmacological survey
During an ethnopharmacological survey carried out
between July to December 2007 in the province of Méd-
ina Sabakh (Western-Center of Senegal), based on a
questionnaire, ten healers and members of the local
population were interviewed to determine on which
symptoms their diagnosis/feeling of suspected malaria
was based, which parts of plants were used to prepare
the traditional treatment for the suspected malaria, how
it was administrated, and finally whether these tradi-
tional treatments were effective on the observed
symptoms.
Following this investigation, the traditional diagnose of
suspected malaria was based on observation of fever,
strong headache, chills, vomits, loss of apetite, increased
fatigue. These symptoms were observed in particular
during the rainy season in Senegal (June to October).
The fever was the most known symptom for a suspected
malaria. For better efficiency, the traditional treatment
was supposed to be administered at the onset of clinical
symptoms.
The survey revealed seven plants traditionally used for
malaria treatment in Senegal: Azadirachta indica (leaves
and stem bark), Khaya senegalensis (stem bark), Anogeis-
sus leiocarpus (stem bark), Ficus gnaphalocarpa (stem
bark), I. senegalensis (leaves), Nauclea latifolia (leaves,
stem bark and roots), Cassia occidentalis (leaves). A lit-
erature review (ScienceDirect, PubMed, Napralert, Sci-
Finder) indicated that among the plants used in
traditional malaria treatment in Senegal and revealed by
this survey, I. senegalensis had until today not been
studied for its anti-plasmodial activity. All ten traditional
healers interviewed revealed that they used Icacina
leaves powder to treat successfully “malaria”. This plant
was also well known by the local population.
Selection and collection of plant materials
Icacina senegalensis (Icacinaceae) leaves (Figure 1A)
used against malaria and symptoms that can be possibly
related to malaria, were harvested in October 2007 in
the plant’s natural habitat in the province of Médina
Sabakh. This area is in 274 km distance from the capital
Dakar and lies within the geographical coordinates of
15°34’W and 13°35’N (Figure 2). The leaves were col-
lected early in the morning before sun set as the local
population who take decoction and maceration of pow-
dered leaves usually do. After identification at the
Dakar’s Laboratoire de Pharmacognosie et Botanique
(M. Fall Ibrahima and Dr William Diatta), a voucher
specimen SS 005 was deposited at the herbarium of the
Faculté de Médecine, Pharmacie and Odonto-Stomato-
logie of Dakar. This plant is not featured in the World
Conservation Union’s (IUCN) red list of threatened spe-
cies and its harvest is not prohibited (IUCN red list).
Plants extraction, extracts partition and fractionation
The plant material (5 kg) consisted of leaves of I. sene-
galensis without stems. The leaves were air-dried at
room temperature (approximately 30°C) on a laboratory
bench, safe from the light during ten days (Figure 1B).
They were cut out and ground with a knife crusher
(Illico, Moulinex, France), then, in a grinder Sprex Sam-
plePrep 6870 Freezer Mill cryogenic (Sprex, Metuchen,
New Jersey, USA).
Methanol was used as polar solvent extraction. Forty
grams of the powdered plant material (0.2 mm) was
submitted to three successive 90-min Soxhlet extrac-
tions (Isolab, Wertheim, Germany) with analytical grade
methanol (120 mL). The three organic extracts were
pooled. The methanolic extracts named IM were evapo-
rated to dryness under vacuum (35°C, 150 mbar) (Rota-
vapor, Büchi, Sweden). As some moisture remained in
the powder, it was resuspended in 10 mL of purified
milliQ+ water (Millipore, Molsheim, France), transferred
in lyophilization vessels, freeze dried (Alpha 2-4 LSC/
Bioblock Scientific, Strasbourg, France) and stored at
+4°C safe from light.
The freeze-dried methanolic extract (IM) was redis-
solved in 100 mL water/methanol (20/80; v/v) by sonica-
tion (Sonorex RK100, Bandelin Electronic, Berlin,
Germany) during 30 min and then partitioned with 3 ×
40 mL pentane. The pentane fraction (IMP) was dis-
carded whereas the water one was partitioned with 3 ×
40 mL dichloromethane to give apolar (IMD) and polar
fractions (IMW) which were both freeze dried and
Sarr et al. Malaria Journal 2011, 10:85
http://www.malariajournal.com/content/10/1/85
Page 2 of 10
stored under safe light conditions at +4°C before testing.
Finally the three fractions named IM, IMD and IMW
were tested for their anti-plasmodial activity on P. falci-
parum 3D7 Africa and P. falciparum 7G8 Brazil strains
respectively chloroquine-sensitive and chloroquine-
resistant.
The most active fraction (IMD) (200 mg) was sepa-
rated on Sephadex LH-20 ®(GE Health care, Uppsala,
Sweden) column (Length = 32 cm, Internal Diameter =
2.5 cm) with methanol/water (80:20; v/v) (1 L) as eluent.
The subfractions (10 mL each) obtained were screened
by means of high performance liquid chromatography
(HPLC) system with diode array detection (DAD)
(Acquity, Waters corporation, MA, USA). The chroma-
tographic separations were performed on a Kinetex®
C18 column (2.6 μm, 2.1 × 150 mm) (Phenomenex, Le
Figure 1 Icacina senegalensis at different development stages (A) and dried leaves (B).
Figure 2 Map of Senegal showing plant area collection.
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Pecq, France) maintained at 30°C and eluted with a lin-
ear methanol-aqueous formic acid (0.11%; v/v) gradient
up to 19 min at 250 μL/min, starting at 10% methanol
and rising to 80% over the course of the gradient. A
volume of 2.5 μL of IMD fractions (100 ppm) was
injected. Only analytical grade solvents (HPLC-quality)
and reagents were used. The DAD conditions were: 320
nm, Max plot or spectra 200-500 nm, resolution at 1.2
nm, sampling rate at 20 points/sec (pps, Hz).
Subfractions with similar chromatographic profile
were then pooled and gave three fractions Da (subfrac-
tions 1 to 10), Db (subfractions 11 to 25) and Dc (sub-
fractions 26 to 100) which were also tested for
cytotoxicity and in vitro activity on both 3D7 and 7G8
P. falciparum strains.
Preparation of samples and controls
Samples and controls are prepared identically with 0.5%
dimethylsulfoxyde (DMSO) at maximal final concentra-
tion in Malaria Culture Medium (MCM). It was a modi-
fication of that described in a previous culture method
[12] and consisted of RPMI 1640 with glutamax®
(Gibco, Cergy-Pontoise, France) supplemented with 10%
(v/v) foetal calf serum, 25 mM HEPES, 1 μg/mL hypox-
anthin, 0.11 mg/mL sodium pyruvate and 0.02 mg/mL
gentamicin. Stock solutions of plant extracts at 1 mg/
mL in MCM were used to prepare the test samples.
When necessary, solubilization of samples was assisted
by sonication (Sonorex RK100, Bandelin Electronic, Ber-
lin, Germany).
For anti-plasmodial test, two negative controls were
MCM and a freeze-dried methanolic extract of Khaya
senegalensis stem bark prepared identically as IM from
plants harvested in Senegal while chloroquine was the
positive control. Concerning the plant used as negative
control, a previous study showed that Khaya senega-
lensis stem bark methanolic extract gave an IC50 on
3D7 of 150 μg/mL while butanolic and aqueous
extracts gave respectively IC50s of 500 and 100 μg/mL
on P. falciparum Dd2, a chloroquine-resistant strain
[13]. Also the ethanolic extract of K. senegalensis gave
IC50 of 82 μg/mL on fresh clinical isolates of P. falci-
parum [14]. These results justify the use of this plant
extract as negative control besides the extracts dissolu-
tion solvents, which showed no effect on parasite
growth.
Parasite strains and in vitro culture
Plants extracts were tested on strains of P. falciparum
3D7 Africa (chloroquine-sensitive) and 7G8 Brazil
(chloroquine-resistant) (Laboratoire de Parasitologie,
Centre National de Référence du Paludisme, Hôpital
Bichat-Claude Bernard, and Université Paris Descartes,
EA 209, Paris, France).
Uninfected human blood group O+ erythrocytes used
as host cells were obtained from healthy donors (Etablis-
sement Français du Sang, Strasbourg, France) and con-
served in SAGM (Saline Adenine Glucose Medium) at
37.5% (v/v) (Sigma Aldrich, St Quentin Fallavier,
France).
This preparation was washed with RPMI 1640 med-
ium before every use and the stock solution prepared at
a 50% haematocrit. The strains were routinely main-
tained in continuous long-term cultures at the Institut
de Parasitologie et de Pathologie Tropicale (Strasbourg,
France) at 37°C in an atmosphere of 3% O2, 5% CO2
and 91% N2 (Sanyo O2/CO2 incubator, model MCO-
5M, Avon, France). The parasite density was maintained
at 1% parasitaemia. The parasitaemia is calculated as
being the number of erythrocytes parasitized when
observing 10 microscopic fields (Zeiss, Axioskop, Ger-
many). Before each anti-plasmodial test, parasite cul-
tures were synchronized in a ring stage obtained from
serial treatment with 5% D-sorbitol [15].
Haemolytic activity
It was done according to a modified method previously
described [16]. Briefly, the extracts were serially diluted
in MCM at concentrations ranging from 1 to 100 μg/
mL in 96-well culture plates and each concentration
incubated with the same volume (100 μL) of non-
infected erythrocytes (5% haematocrit). After 40 min of
incubation at 37°C under circular agitation (Titramax
100 Heidolph, Schwabach, Germany), erythrocytes were
sedimented in the microtitre plate wells by centrifuga-
tion (400 g for 7 min) (Fisher Bioblock Scientific, Ill-
kirch, France). The supernatants were diluted 1:4 in
distilled ultra pure water in separate microtitre plates.
An haemolytic agent, 5% Sodium Dodecyl Sulfate (SDS),
was used as positive control. Negative control contained
erythrocytes diluted (v/v) with the sterile MCM. Haemo-
lytic effect of chloroquine was also evaluated. Haemo-
globin content in the supernatants was determined by
absorbance measurements at 538 nm in a microtiter
plate spectrophotometer (ELX 808, Bio-Tek, Winooski,
USA).
Cytotoxicity assay
The cytotoxicity was assessed in culture on hepatic
mouse cells Hepa 1-6 obtained from the American Type
Culture Collection (ATCC® Number: CRL-1830, Mana-
ssas, USA) and on Normal Human Dermal Fibroblasts
(NHDF) cells (PromoCell, Heidelberg, Germany). The
assessment was performed in order to determine selec-
tivity indexes (SI) which represents the ratio of cytotoxi-
city to anti-plasmodial activity.
To estimate the half max inhibitory concentration for
cytotoxicity (IC50), the 3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT) (Sigma Aldrich, St
Quentin Fallavier, France) enzymatic micromethod was
used [17]. Hepa 1-6 cells were cultured in suspension in
complete Dulbecco’s Modified Eagle Medium (DMEM)
containing 10% heat-inactivated fetal calf (FCS) (alpha-
calf) in the presence of 5% CO2 at 37°C. Medium was
renewed at 2-days intervals. NHDF cells were cultured
in Fibroblast Growth Medium Kit (PromoCell, Heidel-
berg, Germany) in the presence of 5% CO2 at 37°C.
Cells were harvested and washed by centrifuging for
10 min at 400 × g, then counted and adjusted to a final
concentration of 5 × 104 cells/well in 24-well-flat-bot-
tom microplates (Nunc). Hundred microlitres of culture
medium were added to each well containing cells. Plant
extracts were dissolved in DMSO (with a final concen-
tration not exceeding 0.5%) to prepare stock solutions at
1 mg/mL. The stock solutions were diluted with the cul-
ture medium to obtain the desired test concentrations.
Then, 100 μL of each extract solution was added to cells
at fifteen different concentrations ranging from 1 to 500
μg/mL. Cells were incubated at 37°C with 5% CO2.
After 24 h of incubation, the supernatant was removed
and 100 μL of MTT (0.5 mg/mL) was added to each
well [18]. Plates were further incubated for 3 h. The
enzymatic reaction was then stopped by addition of 100
μL of a mixture of ethanol-DMSO (50:50; v/v). The
plates were incubated for an additional 30 min under
agitation at room temperature. The solution was trans-
ferred into a 96-well plate to measure the absorbance at
570 nm using a microtiter plate spectrophotometer
(ELX 808, Bio-Tek, Winooski, USA). Cells cultivated in
absence of treatment but maintained under the same
conditions were used as control. Cytotoxicity of chloro-
quine was also tested on cells.
In vitro anti-plasmodial assay
Parasites in culture medium were used as a negative
control and represented 100% parasite viability. The
positive controls consisted of chloroquine diphosphate
(Sigma-Aldrich, Saint Quentin Fallavier, France), at con-
centrations varying between 0 and 100 nM for P. falci-
parum 3D7 strain. For P. falciparum 7G8 strain, tested
chloroquine concentrations reached 1.5 μM.
Extract testing was performed three times in triplicate
in a 96-well culture plate with cultures mostly at ring
stages at 1% parasitaemia (haematocrit, 2%). Parasite
culture (130 μL) was incubated with each extract (130
μL) for 96 h at 37°C in an atmosphere of 3% O2, 5%
CO2 and 91% N2 (Sanyo O2/CO2 incubator, model
MCO-5M, Avon, France). All reagents and buffers used
for the pLDH test were from Diamed (DiaMed, Cressier
s/Morat, Switzerland). The anti-malarial activity of plant
extracts was evaluated by the pLDH immunodetection
assay with a commercially available sandwich enzyme-
linked immunosorbent assay following manufacturer
recommendations. Briefly, the test contains ELISA plates
already coated with a monoclonal antibody (MAb)
against pan-pLDH. After addition of lysis buffer (100
μL), 50 μL of the incubated parasitized supernatant cul-
ture and 50 μL of pLDH controls (positive and nega-
tive), the ELISA plates were incubated for 1 h at 37°C
under soft shaking and washed with phosphate buffer.
After the addition of 100 μL per well of a biotinylated
MAb against pan-pLDH, the plates were incubated for
30 min at 37°C and then washed again with phosphate
buffer. A third incubation for 15 min at 37°C with 100
μL of a streptavidin horse radish peroxidase solution
was followed by a last washing step (phosphate buffer).
Enzyme activity was revealed by incubation for 15 min
at 37°C with 100 μL of tetramethylbenzidine. The reac-
tion was stopped with 50 μl of 0.5 M sulfuric acid and
the absorbance was read with a microplate spectrophot-
ometer (ELX 808; Bio-Tek, Winooski, USA) at 450 nm
[9,19]. The absorbance values from negative control
wells (containing only MCM and the culture) were
referred to as having 100% pLDH activity.
Selectivity indexes
The selectivity index is defined as the ratio of the IC50
value determined on the NHDF cells (cytotoxicity) on
the IC50 value determined on P. falciparum 3D7 (anti-
plasmodial activity).
Data analysis
All results included IC50 (concentration at which the
parasite growth was inhibited by 50%) are reported as
mean ± standard deviation (SD) of three independent
experiments. For each experiment, concentrations were
tested in triplicate in a 96-well plate. For anti-plasmodial
and cytotoxicity activities the 50% inhibitory concentra-
tion (IC50) was calculated using nonlinear regression
method. The model is an inhibitory sigmoid Emax
model [10]. Student-test was used to compare data at
95% confidence limit.
Results
Plant extraction
Methanolic extract and fractions of I. senegalensis were
tested in vitro on P. falciparum chloroquine-sensitive
(3D7) and chloroquine-resistant strains (7G8) for their
anti-plasmodial activity. The yield is calculated as
being the ratio of the mass of the extract on that of
the starting dried powder. Thus, after methanolic
extraction, freeze drying and partition, the yields
obtained were (5.6 ± 0.75) %, (2.9 ± 0.8) % and (0.6 ±
0.2) % respectively for IM, IMW and IMD. After frac-
tionation of IMD on Sephadex LH-20® column, sub-
fractions Da, Db and Dc represented respectively
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20.5%, 14.6% and 60.2% of IMD. Approximately, 4% of
products were lost during evaporation and freeze-dry-
ing process of subfractions.
Haemolytic activity and cytotoxicity of extracts
Methanolic extracts and their fractions of I. senegalensis
were evaluated for their haemolytic activity. Haemolytic
effect observed with these extracts was always below the
limit of detection and the same as the one observed
with the solvent (MCM) which is considered in this test
as a negative control; whereas the maximum haemolytic
effect (100%) was observed with SDS (5% m:v) consid-
ered as positive control.
The cytotoxicity evaluated on Hepa 1-6 cells revealed
IC50 as high as 133 ± 20 μg/mL, 122 ± 4 μg/mL and
447 ± 6 μg/mL for IM, IMD and IMW. Also no toxicity
was observed on NHDF cells with extracts even at con-
centrations as high as 500 μg/mL. Table 1 summarizes
the cytotoxicity against cells used as well as selectivity
indexes of the plant extracts which remained above 35
whatever the extract sample was.
In vitro Plasmodium falciparum growth inhibition
The P. falciparum 3D7 (chloroquine-sensitive) and 7G8
(chloroquine-resistant) strains used gave, with chloro-
quine, IC50s of 44 ± 1 nM and 658 ± 14 nM respec-
tively. No measurable effect on parasite survival was
observed in MCM containing DMSO at 0.5% and even
with the freeze-dried methanolic extract of Khaya sene-
galensis stem bark which IC50 on 3D7 strain was higher
than the highest concentration investigated (100 μg/
mL). Anti-plasmodial activities of extract, fractions and
subfractions are presented in Tables 1 and 2.
Da, Db and Dc are fractions obtained after separation
of IMD on a Sephadex LH-20® column.
Fraction IMD and subfraction Db of I. senegalensis A.
Juss. leaves extract exhibited the highest inhibition with
IC50 of 4.1 ± 0.1 μg/mL and 0.94 ± 0.06 μg/mL on P.
falciparum 7G8 strain (chloroquine-resistant). Their
chromatographic profiles are presented in Figure 3.
Discussion
Indigenous to western and central Africa, I. senegalensis
is found growing wild on light sandy soils in the savan-
nah areas of Senegal, Gambia, Northern Ghana, Guinea,
Nigeria and parts of Sudan [20]. In Senegal, I. senegalen-
sis mature leaves powdered are decocted and prescribed
by healers against malaria and fevers. About 50 g of
dried leaves are boiled in 1 L of water during 1 to 2 h.
Leaves decoction is often mixed with honey to ovoid
unpleasant taste. A posology of a cup of coffee (50 mL)
three times per day for adults usually for 7 days is
usually prescribed.
A bibliographic research related to the bioactivity of I.
senegalensis revealed only antihyperglycemic activity of
the leaves ethanolic extract [21]. Also a phytochemical
study done on the plant tuber revealed the presence of
icacenone (0.08%), icacinol (0.03%), b-sitosterol (55%),
stigmasterol (45%) and hardwikiol linoleate [22,23].
Because I.senegalensis is traditionally taken against
fevers and malaria after decoction with water, metha-
nol, a polar solvent was used for plant extraction.
However, it is so important to make sure that the use
of the drug does not present toxic effects for human
health. Thus, before starting in vitro evaluation of P.
falciparum susceptibility to natural extract, the haemo-
lytic activity of the extracts was evaluated on red blood
cells with high concentrations exceeding those used in
this work and reaching 100 μg/mL. A preliminary
investigation of the freeze dried methanolic extract
Table 1 Anti-plasmodial activity, cytotoxicity and selectivity indexes of extracts IM, IMD and IMW
Extracts IC50 ± SD* (μg/mL) for P. falciparum strains IC50 (Hepa 1-6
+
)(μg/mL) IC50 (NHDF
+
)(μg/mL) SI
3D7 7G8
IM 4.7 ± 0.2 8 ± 1 133 ± 20 > 500 > 106
IMD 0.9 ± 0.2 4.1 ± 0.1 122 ± 4 > 500 > 500
IMW 14.2 ± 0.7 32 ± 2 447 ± 16 > 500 > 35
Chloroquine (nM) 44 ± 1 658 ± 14 > 800 > 800 > 18
* Standard deviation
+NHDF: Normal Human Dermal Fibroblasts
+Hepa 1-6: Mouse hepatocytes
IM: Methanol extract of I. senegalensis leaf extract, IMD: Apolar fraction of IM
IMW: Polar fraction of IM, SI: selectivity index.
Table 2 Anti-plasmodial activity of fractions Da, Db and
Dc
Fractions from IMD IC50 ± SD (μg/mL) for P. falciparum strains
3D7 7G8
Da 3.2 ± 0.2 1.7 ± 0.1
Db 2.56 ± 0.02 0.94 ± 0.06
Dc 4.2 ± 0.08 4.1 ± 0.1
Da, Db and Dc are fractions obtained after separation of IMD on a Sephadex®
LH-20 column.
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toxicity of I. senegalensis revealed no haemolytic effect
in vitro on red blood cells. These first results, which
were not amount-dependant, tended to confirm the
traditional use by oral way of the decoctions and
macerations of these natural extracts by the auto-
chtone populations with a long history of use and
without side effects. The haemolytic activity was of the
same order of magnitude as those of negative control
and chloroquine, a pure well tolerated molecule.
Because metabolism of xenobiotic taken by oral route
as I. senegalensis leaf extract take place principally in the
liver, it appeared important to evaluate the cytotoxic
activity of active extracts on mouse hepatic cells (Hepa
1-6). The cytotoxicity test on Hepa 1-6 cell line revealed
IC50 > 100 μg/mL for methanolic extract from I. senega-
lensis leaf and all obtained fractions (Table 1). As well,
no toxicity was observed on NHDF cells (IC50 > 500 μg/
mL). It is generally considered that pharmacological effi-
cacy is not due to in vitro cytotoxicity when selectivity
index (SI) >10 [24,25]. Consequently these extracts can
be considered no toxic since all calculated selectivity
indexes are higher than 35 (Table 1). This let us believe
that activity obtained with I. senegalensis leaves extracts
is not due to general toxicity against P. falciparum but
can be explained by specific anti-plasmodial activity.
These high selectivity indexes enabled further investiga-
tions on extracts and should offer the potential for safer
therapy.
This in vitro evaluation of anti-plasmodial activity of I.
senegalensis leaf extracts, showed that IC50 of IM, IMD
and IMW were respectively 4.7 ± 0.2 μg/mL, 0.9 ± 0.2
μg/mL and 14.2 ± 0.7 μg/mL on P. falciparum chloro-
quine-sensitive 3D7 strain, and 8 ± 1 μg/mL, 4.1 ± 0.1
μg/mL and 32 ± 2 μg/mL on chloroquine-resistant P.
falciparum 7G8 strain (Table 1).
Recently, stringent endpoint criteria were set for anti-
plasmodial activity, taking selectivity in account. Then
relevant activity relates IC50 values below 100 μg/mL for
extracts [26] and below 25 μM for pure compounds
[27]. In this work, it is observed that all extracts gave an
IC50 below 20 μg/mL (Table 1). This can be explained
by non exhaustive and specific partition of active com-
pound(s) between polar and apolar solvents and/or with
presence of different active compounds in I. senegalensis
leaf extract. So the active molecule(s) could be present
in variable amount in both three extracts IM, IMD and
IMW. The extract IM showed good anti-plasmodial
activity but was less active on 3D7 and 7G8 strains than
the defatted extract and partitioned extract IMD. This
results can be explained by the fact that IM not defatted
with pentane contained many pentane soluble fatty
impurities which may reduce the anti-plasmodial activity
and emphasize on the importance of extraction and pur-
ification protocols to confirm traditional use of plants.
The less active extract was IMW which is the most
polar one. Nevertheless, it was noted that the most
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Figure 3 Chromatographic profiles of IMD and subfractions Da, Db et Dc in similar conditions.
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active extract (IMD) gave an IC50 below 5 μg/mL (4.1 ±
0.1 μg/mL) on P. falciparum 7G8 strain and below 1
μg/mL on P. falciparum 3D7 strain. This extract showed
predominant compounds in its chromatographic profile
(Figure 3).
With the aim to find active subfractions and conse-
quently identify the active substance(s) on P. falciparum,
IMD was fractionated on a Sephadex LH-20® column
eluted by mixture of MeOH-H20 (80:20, v/v) to produce
three subfractions Da, Db and Dc. These subfractions
contain compounds which are chemically different as
shown by the chromatographic profiles (Figure 3). Table
2 shows very active subfractions with IC50 < 5 μg/mL.
Nevertheless Db is significantly the most active one on
both 3D7 and 7G8 strains with IC50 respectively of 2.56
± 0.02 μg/mL and 0.94 ± 0.06 μg/mL (p < 0.05).
The IC50 of Dc is equal to that of IMD on P. falci-
parum 7G8 strain. This means that Dc explains alone
the activity of IMD and there is no need for Da and Db
to explain the activity of IMD. This observation can be
explained, taking into account the yields obtained after
chromatographic separation. The amount of Dc present
in IMD is 4 and 3 fold higher than those of Db and Da.
With the hypothesis that Da, Db and Dc inhibit P. falci-
parum 7G8 strain growth by a similar mechanism
implying the same sites of action, Dc action is predomi-
nant in IMD. Then Dc will saturate the sites of action
and there is no need of Da and Dc to justify the activity
of IMD. Nevertheless, when tested separately, Da and
Db can act on the Plasmodium without any competition
on the same sites of action and showed higher anti-plas-
modial activity (1.7 μg/mL and 0.8 μg/mL) than Dc (4.1
μg/mL) on the chloroquine-resistant strain 7G8. Consid-
ering the IC50 values obtained on this strain, it appears
that the anti-plasmodial activity of Dc is 4.5 fold and 2.4
fold lower than those of Db and Da. One can see that
these anti-plasmodial activities are correlated with the
yields obtained after fractionation. The best anti-plasmo-
dial activity obtained with Db on the chloroquine-resis-
tant strain justifies our choice to prioritize this
subfraction for further investigations.
Concerning the chloroquine-sensitive strain 3D7, it
appears that the subfractions act by a different mechan-
ism than that used on the chloroquine-resistant strain.
Da, Db and Dc seem to act by different sites of action.
Then their activities are additive in IMD which gave a
best anti-plasmodial activity on the 3D7 strain (0.9 μg/
mL). The fractionation does not give better anti-plasmo-
dial activity than IMD and appears not useful concern-
ing the 3D7 strain.
The fact that IMD extract present surprisingly higher
activity compared to the ones of Da, Db and Dc (on the
3D7 strain only) can be explained mainly by a synergis-
tic activity and incidentally by the loss of synergizing (or
active) components during the process of fractionation.
Indeed fine fractionation can lead to loss of activity due
to decomposition or transformation of active constitu-
ents to less active substances (oxidation of phenolic
compounds for example). Many plant extracts contain
antioxidant compounds, which might protect labile sub-
stances in a crude extract but, upon fractionation such
protective substances might become separated from the
susceptible compounds, so that the later are quickly oxi-
dised [28].
The IC50 of Db on P. falciparum 7G8 strain (0.94 μg/
mL) was lower than that on P. falciparum 3D7 strain.
This shows that there is no correlation between IC50
value obtained with Db and the chloroquine-sensitivity
of the strain tested. This phenomenon was described by
several authors testing anti-plasmodial activity of natural
products [29-31].
Theses IC50 values seemed sufficiently potent to war-
rant further biological investigation on Db and to iden-
tify active principle(s).
According to the WHO recommandations and previous
works [32-34], anti-plasmodial activities of plant extracts
were classified as follows: highly active extracts with IC50
< 5 μg/mL, promising activity at 5-15 μg/mL, moderate
activity at 15-50 μg/mL and inactivity at > 50 μg/mL.
Many plants belonging to other traditional medicines
gave active extracts and very active purified molecules
against P. falciparum strains. Nevertheless, the results of
this study can be compared to those of known anti-plas-
modial plants such as Nauclea latifolia, the stem bark’s
decoction of which not purified gave an IC50 of 1.7 ± 0.3
μg/mL on Nigerian chloroquine-sensitive strain (IC50 for
chloroquine: 35 ng/mL) [35]. Plants considered as refer-
ence drugs by numerous authors because of their wide use
in traditional medicine, have IC50s against chloroquine-
resistant strains of 3.9 μg/mL (Artemisia annua) [36],
2.35-12.6 μg/mL (Azadirachta indica) [37] and 2.2 ± 0.4
μg/mL (Nauclea latifolia) [35] in similar experimental
conditions. Compared to the results obtained with the Db
fraction on chloroquine-resistant 7G8 strain (0.94 μg/mL),
I. senegalensis shows an anti-malarial potential which can
be revealed by a bioguided fractionation and a fine isola-
tion of the active organic compounds.
It is the first scientific demonstration that I. senegalen-
sis leaves extracts inhibit P. falciparum strains 3D7 and
7G8 growth at low concentration far below 5 μg/mL,
and with satisfactory selectivity indexes. The selectivity
indexes higher than 10 suggest that the anti-plasmodial
activity of I. senegalensis is not due to general toxicity
but can be explained by specific activity.
Conclusion
The results achieved with this work constitute a proof that
I. senegalensis, discovered by an ethnopharmacological
Sarr et al. Malaria Journal 2011, 10:85
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survey, is a promising plant with regard to anti-malarial
phytotherapy research and support continuous investiga-
tion of natural resources to discover new anti-malarials.
Although these results add interesting informations to
malaria research, the present study is preliminary. The
next step will consist to identify the active compound (s)
of I. senegalensis, to synthesize analogues and to run in
vivo studies.
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